Proliferation (log 2 doublings, 5 days) of 786-O transduced with a sgControl or sg VCAN under the indicated concentrations of ML162
Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%
Rather than pushing toward the maximum dose used in obesity trials, a clinician might: Start at a lower dose than usual Increase more slowly or pause increases for longer Stop escalating when acceptable appetite control and side-effect balance are reached, even if the dose is below the typical obesity dose This is where terms like microdosing guide and microdose guide show up online
At 6 months, patients who discontinued treatment within 0-3 months had a -1.8% weight change, while those persistent for 12 months saw an -8.1% change
After washing, the slides were dehydrated, cleared, and mounted with neutral resin
